26.02
Sensei Biotherapeutics Inc (SNSE) 最新ニュース
Sensei Biotherapeutics Secures 200 Million Dollars for Oncology Pipeline - HarianBasis.co
Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer - PharmiWeb.com
Sensei Biotherapeutics begins trial of PIKTOR in breast cancer By Investing.com - Investing.com Australia
Sensei Biotherapeutics begins trial of PIKTOR in breast cancer - Investing.com
10 Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Short Selling Surges in Small-Cap Healthcare Stocks Amid Bearish Sentiment - GuruFocus
[144] Sensei Biotherapeutics, Inc. SEC Filing - Stock Titan
Sensei Biotherapeutics (SNSE) price target increased by 53.85% to 51.00 - MSN
Sensei Biotherapeutics (NASDAQ: SNSE) registers 24.87M resale shares - Stock Titan
[ARS] Sensei Biotherapeutics, Inc. SEC Filing - Stock Titan
Faeth-focused recapitalization at Sensei (NASDAQ: SNSE) reshapes ownership and adds $200M - Stock Titan
Sensei Biotherapeutics (SNSE) Stock: Risk vs Return Evaluation | Q4 2025: EPS Exceeds ExpectationsTrending Social Stocks - Newser
Is Sensei Biotherapeutics (SNSE) stock a favorable investment idea | Q4 2025: EPS Exceeds ExpectationsCrowd Breakout Signals - Xã Thanh Hà
Is Sensei Biotherapeutics (SNSE) stock facing investor skepticism | Q4 2025: Earnings Beat EstimatesHot Momentum Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Is Sensei Biotherapeutics (SNSE) stock relatively low risk (Market Focus) 2026-04-22High Beta Stocks - Xã Vĩnh Công
Sensei Biotherapeutics Inc Live Share Prices and Trades. SNSE.US Live Streaming Share Prices. - London South East
Leerink initiates Sensei Biotherapeutics stock at Outperform, $50 target By Investing.com - Investing.com South Africa
Leerink initiates Sensei Biotherapeutics stock at Outperform, $50 target - Investing.com
Sensei Biotherapeutics Announces Leadership and Board Transitions - The Globe and Mail
Sensei Biotherapeutics: If Proposals Are Approved, COO Anand Parikh Is Expected to Become CEO - Moomoo
Christopher W. Gerry, Thomas Ricks, and Kristian Humer Tender Conditional Resignations From Sensei Biotherapeutics Board, Effective in June - Moomoo
Leadership and board overhaul outlined by Sensei Biotherapeutics (NASDAQ: SNSE) - Stock Titan
Faeth deal shifts control; Sensei Biotherapeutics (NASDAQ: SNSE) seeks shareholder approvals - Stock Titan
Form 8-K/ACurrent report: [Amend] - ADVFN
Sensei Biotherapeutics (SNSE) details Faeth acquisition, PIPE and going-concern warning - Stock Titan
Sensei Biotherapeutics (SNSE) grants PFO 80,000 stock options - Stock Titan
Director at Sensei Biotherapeutics (SNSE) receives 23,100 stock options - Stock Titan
Sensei Biotherapeutics Inc and Faeth Therapeutics Acquisition Call Transcript - GuruFocus
Macro Review: Is Sensei Biotherapeutics Inc in a bullish channel2026 Trading Recap & Community Consensus Trade Signals - baoquankhu1.vn
Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options - MSN
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - BioSpace
Aug Update: What is the Moat Score of Sensei Biotherapeutics IncQuarterly Market Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Should I Buy Sensei Biotherapeutics (SNSE) Stock Today | Price at $33.00, Up 6.38%Trend Signals - Newser
Investor Mood: What is the Moat Score of Sensei Biotherapeutics IncQuarterly Profit Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Sidley Represents Sensei Biotherapeutics in Acquisition of Faeth Therapeutics - Legal Desire Media and Insights
AI Stocks: Can Sensei Biotherapeutics Inc grow without dilution2026 Catalysts & Trade Opportunity Analysis Reports - baoquankhu1.vn
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update - biospace.com
Sensei Biotherapeutics (SNSE) Sets Ambitious Clinical Goals for 2026 - GuruFocus
Faeth acquisition and $200M raise reshape Sensei Biotherapeutics (NASDAQ: SNSE) - stocktitan.net
Sensei Biotherapeutics Acquires Faeth, Advances PIKTOR Cancer Program with $200M Financing and Reports 2025 Financial Results - Minichart
Sensei Biotherapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update - TradingView
Sensei Biotherapeutics (NASDAQ: SNSE) 2025 loss narrows, lands $200M - Stock Titan
Aug Chart Watch: What is Sensei Biotherapeutics Incs TAM Total Addressable Market2026 WrapUp & Real-Time Market Trend Scan - baoquankhu1.vn
If You Invested $1,000 in Sensei Biotherapeutics, Inc. (SNSE) - Stock Titan
大文字化:
|
ボリューム (24 時間):